Yuwen LiuFounding Partner, Founder at BOHE Angel Fund, Bio2
Founding Partner of BOHE Angel Fund, a 400M RMB fund jointly invested by Wuxi Apptec, Hengrui, Simcere, TigerMed and BGI,etc. This is the first angel fund focusing on healthcare technology-driven start-ups in China, with Xiaodong Wang and Yigong Shi sitting on its scientific advisory board. It has invested into XinKangHe biological, Transcriptic, SmartNuclide, Athelas Therapeutics, CoolLing Biotech, and HighField BioPharmaceutical covering drug discovery, diagnostic and innovative service solutions.
Before she sets up this fund, she was Chairwoman & CEO then executive director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) for 9 years, when she was also Investment Committee Member for BioVENTURE Fund, and Board Director of Innovent, Admera Health, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech. She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies.
She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager. In 2003, she joined Perrigo as first Chief Representative to set up its China operation
She graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI. She is a licensed pharmacist.
She has been invited to participate in several international and domestic conferences as the speaker, like Harvard Chinese Life Science Annual Symposium, Redefining Early Stage Investment Conference，BioPacific Conference, BioCentury Summit in China, Duke International Forum, The Premier China Healthcare Investment Conference, China Bio-Med Innovation and Investment Conference, Bio€quity Europe, Annual Biotech in Europe Forum and Hello Future X-Maker Venture investment program.